Schonfeld Strategic Advisors’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
Other funds holding RNAM
Schonfeld Strategic Advisors's RNAM Position: Q1 2026 in Review
Schonfeld Strategic Advisors sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 439,812 shares — an estimated $31.7M sold.
Schonfeld Strategic Advisors first reported a position in RNAM in Q4 2020 and held it in 8 quarters. The position peaked at $31.7M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Schonfeld Strategic Advisors reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 439,812 Avidity Biosciences shares in Q1 2026, an estimated $31.7M.
- Schonfeld Strategic Advisors first reported a position in Avidity Biosciences in Q4 2020 and held it in 8 quarters.
- Schonfeld Strategic Advisors's Avidity Biosciences position peaked at $31.7M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.